Clinical Trials Logo

Lymphoproliferative Disorder clinical trials

View clinical trials related to Lymphoproliferative Disorder.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01101412 Withdrawn - Lymphoma Clinical Trials

Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium disodium, and ethanol may help prevent blockages and infections from forming in patients with central venous access catheters or peripheral venous catheters. PURPOSE: This randomized trial is studying an antimicrobial solution or saline solution in maintaining catheter patency and preventing catheter-related blood infections in patients with malignancies.

NCT ID: NCT00900120 Withdrawn - Lymphoma Clinical Trials

Collecting and Storing Blood Samples From Patients With Cancer

Start date: March 2004
Phase:
Study type: Observational

RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood samples from patients with cancer.

NCT ID: NCT00621036 Withdrawn - Lymphoma Clinical Trials

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Start date: October 19, 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a person's cancer proteins may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with GM-CSF may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well giving vaccine therapy together with GM-CSF works in treating patients with CNS lymphoma.

NCT ID: NCT00499668 Withdrawn - Lymphoma Clinical Trials

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Start date: August 2007
Phase: N/A
Study type: Interventional

RATIONALE: Antiemetic drugs, such as aprepitant and ondansetron, may help lessen nausea and vomiting caused by opioids. It is not yet known whether aprepitant is more effective than ondansetron in treating nausea and vomiting caused by opioids in patients with cancer. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to ondansetron in treating nausea and vomiting caused by opioids in patients with cancer.

NCT ID: NCT00387530 Withdrawn - Lymphoma Clinical Trials

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

Start date: May 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: The Epstein-Barr virus can cause cancer and lymphoproliferative disorders. Valganciclovir is an antiviral drug that acts against the Epstein-Barr virus. Phenylbutyrate may make cells infected with Epstein-Barr virus more sensitive to valganciclovir. Giving phenylbutyrate together with valganciclovir may block the growth of Epstein-Barr virus-infected cells and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving phenylbutyrate together with valganciclovir works in treating patients with relapsed or refractory Epstein-Barr virus-positive cancer.